From: Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients
sample | resection | age | histology dg. | Survival (months) | sex | RT dose | TMZ dose concomitant | TMZ dose adjuvant/number of cycles | TU size (mm) | TU location | IDH1 status |
---|---|---|---|---|---|---|---|---|---|---|---|
Le | 1st | 57 | giant-cell glioblastoma | 49 | F | NO | NO | NO | 50 | parietal | wt |
 | 2nd | 58 | dtto + postsurgical changes |  |  |  |  |  | 16 | parietal | wt |
 | 3rd | 59 | dtto |  |  |  |  |  | 40 | parietal | wt |
 | 4th | 60 | dtto |  |  |  |  |  | 34 | parietal | wt |
Pu | 1st | 61 | prim.gbm | 44 | M | 60Â Gy | 160 | 400/6 | 20 | temporal | wt |
 | 2nd | 62 | gbm perzistence, postsurgical changes |  |  | 13 Gy (gamma knife) |  |  | 15 | temporal | wt |
 | 3rd | 64 | postsurgical changes, gbm infiltration |  |  |  |  |  | 16 | temporal | wt |
Ku | 1st | 26 | prim.gbm | 55 | M | 60Â Gy | - | - | 37 | tempoparietal | mt |
 | 2nd | 28 | gbm reccurence, postsurgical changes |  |  |  |  |  | 54 | tempoparietal | mt |
Do | 1st | 58 | prim.gbm | 31 | F | 60Â Gy | 140 | 300/12 | 25 | frontal | wt |
 | 2nd | 61 | reccurence |  |  |  |  |  | 35 | frontal | wt |
Jo | 1st | 63 | prim.gbm | 36 | F | 60Â Gy | 140 | NO | 36 | parietal | wt |
 | 2nd | 65 | reccurence, postsurgical changes |  |  | 12 Gy (gamma knife |  |  | 36 | parietal | wt |
Du | 1st | 62 | prim.gbm | 34 | M | 60Â Gy | 140 | 300/6 | 53 | frontal | wt |
 | 2nd | 64 | gbm persistance |  |  |  |  |  | 48 | frontal | wt |
Bi | 1st | 67 | prim.gbm | 24 | F | 60Â Gy | 140 | NO | 38 | temporal | wt |
 | 2nd | 69 | gbm reccurence |  |  |  |  |  | 53 | temporal | wt |
Na | 1st | 38 | prim.gbm | 48 | M | 60Â Gy | 140 | 400/6 | 72 | parietal | mt |
 | 2nd | 41 | gbm reccurence |  |  | 24 Gy (gamma knife) |  |  | 34 | parietal | mt |